Cannabinoid News and Research

Latest Cannabinoid News and Research

GW Pharmaceuticals starts Phase 1b/2a clinical trial for Recurrent Glioblastoma Multiforme

GW Pharmaceuticals plc a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today it has commenced a Phase 1b/2a clinical trial for the treatment of Recurrent Glioblastoma Multiforme.

11 Nov 2013

Brain & Behavior Research Foundation announces recipients of NARSAD Investigator Grants

The Brain & Behavior Research Foundation (formerly known as NARSAD, the National Alliance for Research on Schizophrenia and Depression), under the direction of Dr. Jeffrey Borenstein, President & CEO, has announced the latest recipients of its NARSAD Distinguished Investigator Grants.

8 Nov 2013

Tel Aviv University researchers find chemicals in marijuana could help treat MS

Multiple sclerosis is an inflammatory disease in which the immune system attacks the nervous system. The result can be a wide range of debilitating motor, physical, and mental problems. No one knows why people get the disease or how to treat it.

8 Oct 2013

Almirall and GKV-SV reach agreement on pricing of Sativex medicine in Germany

...

23 Sep 2013

GW Pharmaceuticals starts GWP42006 Phase 1 clinical trial for epilepsy treatment

GW Pharmaceuticals plc announced today it has commenced a Phase 1 clinical trial of product candidate GWP42006 for the treatment of epilepsy.

18 Sep 2013

Cannabis affects addiction processes in adolescent brain

The nature of the teenage brain makes users of cannabis amongst this population particularly at risk of developing addictive behaviors and suffering other long-term negative effects, according to researchers at the University of Montreal and New York's Icahn School of Medicine at Mount Sinai.

27 Aug 2013

Vanderbilt University scientists discover new approach to treating mood, anxiety disorders

Chemically modified inhibitors of the COX-2 enzyme relieve anxiety behaviors in mice by activating natural "endocannabinoids" without gastrointestinal side effects, Vanderbilt University scientists will report next week.

5 Aug 2013

Study: Cannabis has no effect in slowing course of progressive multiple sclerosis

The first large non-commercial clinical study to investigate whether the main active constituent of cannabis (tetrahydrocannabinol or THC) is effective in slowing the course of progressive multiple sclerosis (MS), shows that there is no evidence to suggest this; although benefits were noted for those at the lower end of the disability scale.

24 Jul 2013

GW Pharmaceuticals to expand marketing authorization for Sativex to France

GW Pharmaceuticals plc, a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that it has submitted an application under the European Mutual Recognition Procedure seeking to expand the marketing authorization for Sativex into France for the treatment of spasticity due to Multiple Sclerosis.

22 Jul 2013

Neutra's MMJ subsidiary forms joint venture to market, develop cannabis delivery systems

In a major step forward in its plans to deliver healthier, more effective innovations to the fast-growing medical marijuana industry in the U.S., Neutra Corp. announced today that its MMJ subsidiary, Cannabis Technologies, Inc., has formed a new joint venture with Field of View Technologies, LLC, to market and develop breakthrough cannabis delivery systems.

5 Jun 2013

Report finds increase in unintentional marijuana ingestions among young children

Following modification of drug enforcement laws for possession of marijuana in Colorado, there was an apparent increase in unintentional marijuana ingestions by young children, according to a report and accompanying editorials published Online First by JAMA Pediatrics, a JAMA Network publication.

28 May 2013

Neutra in final stages of negotiations toward new partnership in U.S. MMJ industry

Neutra Corp., a growing provider of all-natural wellness solutions, announced today that it has entered the final stages of negotiations toward a potentially lucrative new partnership in the $1.7 billion U.S. medical marijuana industry.

14 May 2013

Researchers discover connection between CB1 receptors and PTSD

In a first-of-its-kind effort to illuminate the biochemical impact of trauma, researchers at NYU Langone Medical Center have discovered a connection between the quantity of cannabinoid receptors in the human brain, known as CB1 receptors, and post-traumatic stress disorder, the chronic, disabling condition that can plague trauma victims with flashbacks, nightmares and emotional instability.

14 May 2013

New bill could open up new territory for MMJ innovations

As Neutra Corp. works to deliver new innovations making medical marijuana safer and more effective than ever before, the market for such breakthroughs is expanding rapidly. Just last month, two new state legislatures—Pennsylvania and Alabama—saw favorable cannabis bills formally introduced.

8 May 2013

Neuroscientists identify cellular change in the brain that accompanies obesity

A team of American and Italian neuroscientists has identified a cellular change in the brain that accompanies obesity. The findings could explain the body's tendency to maintain undesirable weight levels, rather than an ideal weight, and identify possible targets for pharmacological efforts to address obesity.

30 Apr 2013

Modulation of cerebral endocannabinoid system may help treat Fragile X chromosome syndrome

Researchers at the University of the Basque Country (UPV/EHU) and the Achucarro neurosciences centre have discovered a new therapy for the fragile X chromosome syndrome. This new therapy proposes the modulation of the cerebral endocannabinoid system in order to ameliorate the symptoms of the disease.

11 Apr 2013

Neutra explores smokeless delivery methods for marijuana users

Could the future of medical marijuana be smoke-free? As the market for medicinal cannabis booms across the U.S., Neutra Corp., a provider of all-natural health solutions, is exploring the potential of vaporizers, sprays, edibles, and other smokeless delivery methods to enable marijuana users to enjoy the benefits without the potential side effect of lung damage.

1 Apr 2013

Cannabinoid News and Research

Latest Cannabinoid News and Research

GW Pharmaceuticals starts Phase 1b/2a clinical trial for Recurrent Glioblastoma Multiforme

Brain & Behavior Research Foundation announces recipients of NARSAD Investigator Grants

Tel Aviv University researchers find chemicals in marijuana could help treat MS

Almirall and GKV-SV reach agreement on pricing of Sativex medicine in Germany

GW Pharmaceuticals starts GWP42006 Phase 1 clinical trial for epilepsy treatment

Cannabis affects addiction processes in adolescent brain

Vanderbilt University scientists discover new approach to treating mood, anxiety disorders

Study: Cannabis has no effect in slowing course of progressive multiple sclerosis

GW Pharmaceuticals to expand marketing authorization for Sativex to France

Neutra's MMJ subsidiary forms joint venture to market, develop cannabis delivery systems

Report finds increase in unintentional marijuana ingestions among young children

Neutra in final stages of negotiations toward new partnership in U.S. MMJ industry

Researchers discover connection between CB1 receptors and PTSD

New bill could open up new territory for MMJ innovations

Neuroscientists identify cellular change in the brain that accompanies obesity

Modulation of cerebral endocannabinoid system may help treat Fragile X chromosome syndrome

Neutra explores smokeless delivery methods for marijuana users

CB2 receptors might serve as potential therapeutic targets for cerebral ischemia

Agilent launches new application compendiums on designer drug testing and toxicology of oral fluids

Acetaminophen may improve postoperative outcomes

Cannabis Testing & Analysis eBook

The evolution of OCT for retinal imaging and disease intervention

Supercharging Next-Gen Antibody Discovery with AI and High-Throughput Experimentation

Prof. Dr. Kristina Kusche-Vihrog

Cannabinoid News and Research

Latest Cannabinoid News and Research

Cannabis Testing & Analysis eBook

The evolution of OCT for retinal imaging and disease intervention

Supercharging Next-Gen Antibody Discovery with AI and High-Throughput Experimentation

Prof. Dr. Kristina Kusche-Vihrog

Newsletters you may be interested in